Vaccines Market by Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Technology (Live, Toxoid, Recombinant), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023
[184 Pages Report] The overall market for vaccines is expected to grow from USD 36.45 billion in 2018 to USD 50.42 billion by 2023, at a CAGR of 6.7% from 2018 to 2023. Market growth is attributed to the high prevalence of infectious diseases, growing support for vaccine R&D, investments into vaccine development, and a rising focus on immunization. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.
Market Dynamics
Drivers
Growing government support for vaccine development
The economic and social burdens of pandemics have prompted government bodies globally to increase support for vaccine development. A key example of this is Project Bioshield (US), which aims to counter bioterrorist threats. Other governments have also come forward to provide and encourage vaccine development programs to counter pandemics. For instance, in November 2017, Panacea Biotec (India) received financial assistance of USD 4.32 million (INR 229.9 million) for the development & commercialization of Dengue Tetravalent Vaccine. Similarly, in July 2016, Valneva SE (France) received USD 27.66 million (EUR 25 million) from the European Investment Bank (EIB) for vaccine R&D.
Government organizations are also partnering with the private sector for enhancing vaccine research for diseases that pose a serious threat, such as Zika, Ebola, malaria, and anthrax. Apart from government bodies, other healthcare organizations (such as the Bill & Melinda Gates Foundation) have also increased funding for accelerating the development of advanced infrastructure for vaccine production. The growing availability of funding for vaccine R&D will be a key factor driving market growth, as it will ensure the introduction of new, advanced, and effective products in the coming years.
Restraints
High cost of vaccine development
Vaccine development is a capital-intensive procedure. The development process (from in vitro research to marketing) takes 1015 years and an investment of USD 800 millionUSD 1 billion. Moreover, as the success rate of vaccine development is very low, manufacturers find it challenging to obtain initial investments and manage operational costs.
Furthermore, the storage and distribution cost of vaccines is higher than any other pharmaceutical product, as it requires specialized equipment and monitoring devices. The lack of proper storage and distribution facilities can deteriorate vaccine quality. Thus, the high cost of vaccine development and storage restrains market growth.
Opportunities
Use of adjuvants in vaccines
An adjuvant is used in combination with a specific antigen to enhance the effectiveness of the overall vaccine. Some examples of adjuvants are mineral salts, polyacrylics, carriers, surface-active agents, microparticles, cytokines, and hormones, which are used in vaccines to enhance the bodys immune response. A number of vaccines for hepatitis A, hepatitis B, diphtheria-tetanus-pertussis (DTP), and Hib have aluminum adjuvants in them.
Combined adjuvants are used for increasing the efficacy of vaccines. Companies are researching new adjuvant combinations and novel immunomodulatory molecules to enhance antigen-specific protection from diseases, such as cancer, hepatitis, HIV, and others. For instance, an ISCOM technology-based combined adjuvant is currently in clinical trials and used for studies on infectious diseases. Additionally, various government organizations are providing grants and funds for increasing research on vaccine adjuvants. For instance, in April 2016, the NIAID awarded six grants totaling USD 3.1 million to researchers studying adjuvant vaccine combinations. The increasing significance of such combined adjuvants offers growth opportunities for market players in the coming years.
The following are the major objectives of the study.
- To define, describe, and forecast the global market on the basis of technology, type, disease indication, route of administration, and patient type
- To describe and forecast the market, in terms of value, by regionAsia, Europe, North America, and Rest of the World (RoW) along with their respective countries
- To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders
- To analyze strategic approaches such as product launches, acquisitions, contracts, agreements, and partnerships in the market
During this research study, major players operating in the market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.
Major Developments
- In 2016, Pfizer collaborated with Western Oncolytics to advance Western Oncolytics novel oncolytic vaccinia virus. This collaboration helped Pfizer to enhance its novel technology platform for cancer vaccines and strengthened its immuno-oncology portfolio.
- In 2016, GlaxoSmithKline collaborated with Vaccine Research Center at the NIH (US) to evaluate a new vaccine technology for Zika, known as SAM.
- In 2017, Merck collaborated with Premier, Inc. (US) to develop a preventive care model that seeks to improve adolescent and adult vaccination rates.
- In 2016, Sanofi Pasteur collaborated with The Oswaldo Cruz Foundation (Brazil) and WRAIR (US) to conduct R&D for a Zika vaccine.
Target Audience
- Manufacturers and suppliers of vaccines
- Research and development companies
- Medical research laboratories
- Academic medical centers and universities
- Research and consulting firms
- Venture capital firms
Vaccines Market Report Scope
By Technology
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
By Type
- Monovalent Vaccines
- Multivalent Vaccines
By Disease Indication
- Pneumococcal Disease
- Influenza
- DTP
- Hepatitis
- Human Papilloma Virus (HPV)
- Rotavirus
- Meningococcal Disease
- MMR (measles, mumps, and rubella)
- Varicella
- Polio
- Herpes Zoster
- Dengue
- Other Disease Indications
By Route of Administration
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Other Routes of Administration
By Patient Type
- Pediatrics
- Adults
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
- Asia
- Japan
- China
- India
- Rest of Asia (RoA)
- Rest of the World (RoW)
Critical questions which the vaccines market research report answers
- What are new diseases areas which the vaccines companies are exploring?
- Which are the key players in the market and how intense is the competition?
Available Customizations
Based on the given market data, MarketsandMarkets offers customizations in the reports as per the clients specific requirements. The available customization options are as follows:
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Vaccines are biological products used to enhance the immune response of a body to prevent diseases, such as cholera, typhoid, influenza, and hepatitis. Vaccines may contain weakened/killed microbes, toxins, or surface proteins for inducing immunity against specific diseases.
The report has been segmented, on the basis of technology, conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The market for conjugate vaccine is expected to grow at the highest CAGR between 2018 and 2023. The large share of this segment can primarily be attributed to the increasing government support and rising company investments for conjugate vaccine development.
The market of vaccines in Asia is expected to grow at the highest CAGR during the forecast period. Asia is the fastest-growing market for vaccines. Increasing investments by companies in emerging countries, such as India and China is contributing to the growth of the market.
Monovalent vaccines drive the growth of market
Monovalent Vaccines
A monovalent vaccine is designed to combat a single disease and therefore contains a single strain of an antigen. A number of monovalent vaccines for diseases, such as malaria, Ebola, and dengue are undergoing clinical trials for testing their safety and efficacy. The growing prevalence of these diseases across the globe is a major factor driving market growth.
Multivalent Vaccines
A multivalent vaccine is designed to immunize against several strains or microorganisms, and therefore contains two or more strains/serotypes of the same antigen. Several combined multivalent vaccines are available in the market to protect against DTP, polio, and hepatitis, among other diseases.
Critical questions the report answers:
- Where will all these developments take the industry in the mid to long term?
- What are new diseases areas which the vaccines companies are exploring?
Vaccine development is a capital-intensive procedure. The development process (from in vitro research to marketing) takes 1015 years and an investment of USD 800 millionUSD 1 billion. Moreover, as the success rate of vaccine development is very low, manufacturers find it challenging to obtain initial investments and manage operational costs.
Furthermore, the storage and distribution cost of vaccines is higher than any other pharmaceutical product, as it requires specialized equipment and monitoring devices. The lack of proper storage and distribution facilities can deteriorate vaccine quality. Thus, the high cost of vaccine development and storage restrains market growth.
Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC (US), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi Pasteur (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new products in the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 22)
2.1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 31)
4 Premium Insights (Page No. - 35)
4.1 Overview of the Market
4.2 By Type, 20182023
4.3 By End User, 2018 vs 2023 (USD Billion)
4.4 Geographic Analysis: By Technology
4.5 By Route of Administration, 2018 vs 2023 (USD Billion)
4.6 Geographical Snapshot of the Global Market
5 Market Overview (Page No. - 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.4.2 Product Recalls
6 Industry Insights (Page No. - 46)
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 Hiv
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding
7 Global Market, By Technology (Page No. - 57)
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated and Subunit Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vaccines
7.6 Toxoid Vaccines
8 By Type (Page No. - 65)
8.1 Introduction
8.2 Monovalent Vaccines
8.3 Multivalent Vaccines
9 By Disease Indication (Page No. - 70)
9.1 Introduction
9.2 Pneumococcal Disease
9.3 DTP
9.4 Influenza
9.5 HPV
9.6 Meningococcal Disease
9.7 Polio
9.8 Rotavirus
9.9 Hepatitis
9.10 MMR
9.11 Varicella
9.12 Dengue
9.13 Herpes Zoster
9.14 Other Disease Indications
10 By Route of Administration (Page No. - 87)
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.3 Oral Administration
10.4 Other Routes of Administration
11 Global Market, By Patient Type (Page No. - 92)
11.1 Introduction
11.2 Pediatric Patients
11.3 Adult Patients
12 By Region (Page No. - 97)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 RoE
12.4 Asia
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia (Roa)
12.5 Rest of the World (RoW)
13 Competitive Landscape (Page No. - 127)
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Situation and Trends
13.3.1 Agreements, Partnerships, and Collaborations
13.3.2 Product Launches and Approvals
13.3.3 Acquisitions
13.3.4 Expansions
14 Company Profiles (Page No. - 133)
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 Pfizer
14.2 Glaxosmithkline
14.3 Merck
14.4 Sanofi Pasteur
14.5 CSL Limited
14.6 Emergent Biosolutions
14.7 Johnson & Johnson
14.8 Medimmune, LLC (A Subsidiary of Astrazeneca)
14.9 Astellas Pharma
14.10 Serum Institute of India
14.11 Bavarian Nordic
14.12 Mitsubishi Tanabe Pharma Corporation
14.13 Daiichi Sankyo Company
14.14 Panacea Biotec
14.15 Biological E
*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
15 Appendix (Page No. - 178)
15.1 Discussion Guide
15.2 Knowledge Store: Marketsandmarkets Subscription Portal
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details
List of Tables (93 Tables)
Table 1 Incidence of Diseases
Table 2 NIH Funding for Vaccine Research, 20132018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2015 vs 2016
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investments in HIV Vaccines, By Investor (20152016)
Table 8 Ebola Projects Funded By Ec (20142020)
Table 9 By Technology, 20162023 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Market for Conjugate Vaccines, By Region, 20162023 (USD Million)
Table 12 Examples of Inactivated and Subunit Vaccines
Table 13 Market for Inactivated and Subunit Vaccines, By Region, 20162023 (USD Million)
Table 14 Live Attenuated Vaccines, By Region, 20162023 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines, By Region, 20162023 (USD Million)
Table 17 Toxoid Vaccines, By Region, 20162023 (USD Million)
Table 18 By Type, 20162023 (USD Million)
Table 19 Market for Monovalent Vaccines, By Region, 20162023 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Market for Multivalent Vaccines, By Region, 20162023 (USD Million)
Table 22 By Disease Indication, 20162023 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Vaccines Market for Pneumococcal Disease, By Region, 20162023 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Market for DTP, By Region, 20162023 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Market for Influenza, By Region, 20162023 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Market for HPV, By Region, 20162023 (USD Million)
Table 31 List of Commercially Available HPV Vaccines in the Market
Table 32 Market for Meningococcal Disease, By Region, 20162023 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Market for Polio, By Region, 20162023 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Market for Rotavirus, By Region, 20162023 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Market for Hepatitis, By Region, 20162023 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Market for MMR, By Region, 20162023 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Market for Varicella, By Region, 20162023 (USD Million)
Table 43 Market for Herpes Zoster, By Region, 20162023 (USD Million)
Table 44 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 45 Market for Other Disease Indications, By Region, 20162023 (USD Million)
Table 46 By Route of Administration, 20162023 (USD Million)
Table 47 Market for Intramuscular and Subcutaneous Administration, By Region, 20162023 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 20162023 (USD Million)
Table 49 Market for Other Routes of Administration, By Region, 20162023 (USD Million)
Table 50 By Patient Type, 20162023 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 20162023 (USD Million)
Table 52 North America: Market for Pediatric Patients, By Country, 20162023 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 20162023 (USD Million)
Table 54 North America: Market for Adult Patients, By Country, 20162023 (USD Million)
Table 55 By Region, 20162023 (USD Million)
Table 56 North America: Market, By Country, 20162023 (USD Million)
Table 57 North America: Market, By Technology, 20162023 (USD Million)
Table 58 North America: Market, By Type, 20162023 (USD Million)
Table 59 North America: Market, 20162023 (USD Million)
Table 60 North America: Market, 20162023 (USD Million)
Table 61 North America: Market, By Patient Type, 20162023 (USD Million)
Table 62 US: Market, By Technology, 20162023 (USD Million)
Table 63 US: Market, By Patient Type, 20162023 (USD Million)
Table 64 Canada: Market, By Technology, 20162023 (USD Million)
Table 65 Canada: Market, By Patient Type, 20162023 (USD Million)
Table 66 Europe: Market, By Country, 20162023 (USD Million)
Table 67 Europe: Market, By Technology, 20162023 (USD Million)
Table 68 Europe: Market, By Type, 20162023 (USD Million)
Table 69 Europe: Market, By Disease Indication, 20162023 (USD Million)
Table 70 Europe: Market, By Route of Administration, 20162023 (USD Million)
Table 71 Europe: Market, By Patient Type, 20162023 (USD Million)
Table 72 Germany: Market, By Technology, 20162023 (USD Million)
Table 73 UK: Market, By Technology, 20162023 (USD Million)
Table 74 France: Market, By Technology, 20162023 (USD Million)
Table 75 Italy: Market, By Technology, 20162023 (USD Million)
Table 76 Spain: Market, By Technology, 20162023 (USD Million)
Table 77 RoE: Market, By Technology, 20162023 (USD Million)
Table 78 Asia: Health Expenditure Per Capita, By Country, 2000, 2014 & 2016 (USD)
Table 79 Asia: Market, By Country, 20162023 (USD Million)
Table 80 Asia: Market, By Technology, 20162023 (USD Million)
Table 81 Asia: Market, By Type, 20162023 (USD Million)
Table 82 Asia: Market, By Disease Indication, 20162023 (USD Million)
Table 83 Asia: Market, By Route of Administration, 20162023 (USD Million)
Table 84 Asia: Market, By Patient Type, 20162023 (USD Million)
Table 85 Japan: Market, By Technology, 20162023 (USD Million)
Table 86 China: Market, By Technology, 20162023 (USD Million)
Table 87 India: Market, By Technology, 20162023 (USD Million)
Table 88 RoA: Market, By Technology, 20162023 (USD Million)
Table 89 RoW: Market, By Technology, 20162023 (USD Million)
Table 90 RoW: Market, By Type, 20162023 (USD Million)
Table 91 RoW: Market, 20162023 (USD Million)
Table 92 RoW: Market, 20162023 (USD Million)
Table 93 RoW: Market, By Patient Type, 20162023 (USD Million)
List of Figures (46 Figures)
Figure 1 Market Segmentation
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 By Technology, 20182023
Figure 7 By Type, 2018 vs 2023 (USD Billion)
Figure 8 By Disease Indication, 2018 vs 2023 (USD Billion)
Figure 9 By Route of Administration, 2018 vs 2023 (USD Billion)
Figure 10 By Patient Type, 2018 vs 2023 (USD Billion)
Figure 11 Geographical Snapshot of the Global Market
Figure 12 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 13 Monovalent Vaccines Segment to Register the Highest Growth During the Forecast Period
Figure 14 Pediatrics Segment to Dominate the global Market in 2023 (USD Billion)
Figure 15 Conjugate Vaccines Segment to Hold Largest Share of the Market in 2018
Figure 16 Intramuscular and Subcutaneous Administration Segment to Register the Highest Growth During the Forecast Period
Figure 17 US to Dominate the Global Market in 2018
Figure 18 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Regulatory Approval Process for Vaccines
Figure 20 R&D Funding for HIV Preventive Vaccines, By Investor, 2016
Figure 21 Conjugate Vaccines Segment to Dominate the Market During the Forecast Period
Figure 22 Monovalent Vaccines to Grow at the Highest Rate in the Market, By Type
Figure 23 Pneumococcal Disease Segment to Lead Market, By Disease Indication, During 20182023
Figure 24 Vaccines Market for Dengue, 20162023 (USD Million)
Figure 25 Intramuscular and Subcutaneous Administration Segment to Account for the Market, 20182023 (USD Million)
Figure 26 Pediatric Patients Segment to Account for the Largest Share of the Global Market, 2018 (USD Million)
Figure 27 North America: Global Market Snapshot
Figure 28 Europe: Global Market Snapshot
Figure 29 Asia: Global Market Snapshot
Figure 30 RoW: Global Market Snapshot
Figure 31 Key Developments in the Vaccine Market From 2015 to 2018
Figure 32 Market Evolution Framework
Figure 33 Global Market Share Analysis, By Key Player, 2017
Figure 34 Pfizer: Company Snapshot (2017)
Figure 35 Glaxosmithkline: Company Snapshot (2017)
Figure 36 Merck: Company Snapshot (2017)
Figure 37 Sanofi Pasteur: Company Snapshot (2017)
Figure 38 CSL Limited: Company Snapshot (2017)
Figure 39 Emergent Biosolutions: Company Snapshot (2017)
Figure 40 Johnson & Johnson: Company Snapshot (2017)
Figure 41 Astrazeneca: Company Snapshot (2017)
Figure 42 Astellas Pharma: Company Snapshot (2017)
Figure 43 Bavarian Nordic: Company Snapshot (2017)
Figure 44 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2017)
Figure 45 Daiichi Sankyo Company: Company Snapshot (2017)
Figure 46 Panacea Biotec: Company Snapshot (2017)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Vaccines Market